Range Resources Q2 2026 Results: No Catalyst to Close Valuation Gap

What happened

Range Resources reported its second quarter 2026 results on July 21, 2026, but the announcement lacked the operational or financial detail needed to challenge the stock's premium valuation. The company, a low-cost Appalachian gas producer with 18.1 Tcfe of reserves, continues to trade at roughly 15x trailing earnings and 13x EV/EBITDA, well above conservative DCF and PV-10 anchors. While management maintains disciplined capital allocation and a modest dividend, the pure-play gas exposure, single-basin concentration, and regulatory overhangs leave the stock vulnerable to any gas price disappointment. The most recent financial data through Q3 2025 showed free cash flow turning negative in that quarter, underscoring earnings cyclicality even as the market prices in a robust recovery. Absent a material share-price decline toward the low-to-mid $20s or sustained evidence of a gas price upcycle, the risk/reward remains unfavorable.

Implication

The Q2 2026 release does not alter the fundamental overvaluation thesis; Range still trades at a significant premium to its intrinsic value based on conservative DCF and PV-10. With net debt/EBITDA around 2.1x and interest coverage of 7x, the balance sheet is adequate but not strong enough to justify the current multiple in a cyclical commodity sector. The company's low-cost position and long-life reserves are positive, but they are not unique among Appalachian peers, and the lack of a structural moat means the premium must be supported by gas prices that remain uncertain. Near-term catalysts such as LNG export growth are already priced in, and any regulatory setback (e.g., methane fee rules) could compress margins and force a re-rating. Therefore, existing holders should use any price strength to reduce exposure, and new capital should wait for a pullback to around $20-25 before considering a position.

Thesis delta

The previous DeepValue report assigned a POTENTIAL SELL judgment based on overvaluation relative to DCF and PV-10. The Q2 2026 results, while lacking specific numbers, do not provide any information to narrow that gap. If anything, the continued absence of a positive catalyst and the stock's resilience at ~$35 reinforce the view that the market is overpaying for optionality, shifting the thesis from 'potential sell' to a more concrete 'sell' if the company fails to deliver above-consensus results.